This week’s Medicare updates include the October edition of the Medicare Quarterly Compliance Newsletter, a pair of requests for information on potential usage of artificial intelligence to prevent fraud, Medicare Advantage billing instructions for CAR-T therapy, and more!
Chimeric antigen receptor T-cell (CAR-T) therapy provided to Medicare Advantage (MA) beneficiaries will be paid for by traditional Medicare for calendar years 2019 and 2020.
This spring, CMS changed the scope of work for their Beneficiary and Family Centered Care Quality Improvement Organizations (BFCC-QIO) Livanta and Kepro, which became effective June 8. The QIOs’ responsibilities were narrowed to focus primarily on discharge appeals, quality complaints, and real-time advocacy for Medicare patients and families.
